Renin-angiotensin-aldosterone system(RAAS)plays a central role in circulation system.Suppressing the excessive activation of RAAS can reduce the cardiovascular events.Substantial advances have been made with existing agents—angiotensin-converting enzyme inhibitors(ACEI),angiotensin receptor blockers(ARBs),and new data continue to emerge.New data on angiotensin receptor neprilysin inhibitor(ARNI,a combined ARB and neprilysin inhibitor)show promise for patients with heart failure.This review summarizes recent clinical research on large-scale clinical trials of cardio-protection achieved through ARB. |